公开(公告)号：US20250011733A1

公开(公告)日：2025-01-09

申请号：US18886292

申请日：2024-09-16

Applicant: Codexis Inc.

Inventor： Michael A. Crowe ,  Oscar Alvizo ,  Behnaz Behrouzian ,  Yong Koy Bong ,  STeven J. Collier ,  Anupam Gohel ,  Jagedeesh Mavinahalli ,  Naga K. Modukuru ,  Emily Mundorff ,  Derek J. Smith ,  Shiwei Song ,  Wan Lin Yeo

IPC: C12N9/04 ,  A61K38/00 ,  C07K14/47 ,  C12P17/10 ,  C12P17/14

Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

公开(公告)号：US20240318215A1

公开(公告)日：2024-09-26

申请号：US18579094

申请日：2022-07-12

Applicant: Imperial College Innovations Ltd

Inventor： Kenneth Thomas Walker ,  Thomas Marc Ellis

IPC: C12P19/04 ,  C12N1/20 ,  C12N9/02 ,  C12P17/10

CPC classification number: C12P19/04 ,  C12N1/20 ,  C12N9/0071 ,  C12P17/10 ,  C12Y114/18001

Abstract: The present invention relates to biomaterials, in particular bacterial cellulose and provides means to prepare pigmented cellulose at acidic pH 5.8, wherein cellulose pellicles comprising tyrosinase (EC 1.14.18.1) are melanated using a development solution at pH 6 to 8.5 and comprises tyrosine, cysteine and/or cystine. Further, the invention relates to means of preparing spatially restricted pigmented cellulose using an optogenetic expression system wherein two polymerase or transcription factor domains are split and each linked to a light-inducible dimerization domain. The invention provides corresponding methods and components.

公开(公告)号：US20240141397A1

公开(公告)日：2024-05-02

申请号：US18242912

申请日：2023-09-06

Applicant: Genomatica, Inc.

Inventor： Robin E. Osterhout ,  Priti Pharkya

IPC: C12P17/10 ,  C12N9/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/06 ,  C12N9/10 ,  C12N9/16 ,  C12N15/52 ,  C12P7/18 ,  C12P7/40 ,  C12P7/44 ,  C12P13/00 ,  C12P17/08

CPC classification number: C12P17/10 ,  C12N9/0004 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/001 ,  C12N9/0016 ,  C12N9/1029 ,  C12N9/1096 ,  C12N9/13 ,  C12N9/16 ,  C12N9/93 ,  C12N15/52 ,  C12P7/18 ,  C12P7/40 ,  C12P7/44 ,  C12P13/001 ,  C12P13/005 ,  C12P17/08 ,  C12Y101/01027 ,  C12Y101/0103 ,  C12Y101/01035 ,  C12Y101/01037 ,  C12Y101/01172 ,  C12Y103/01031 ,  C12Y104/01009 ,  C12Y203/01174 ,  C12Y206/01019 ,  C12Y208/03006 ,  C12Y301/02004 ,  C12Y603/03004

Abstract: Provided herein are non-naturally occurring microbial organisms having biosynthetic pathways for production of target products and one or more genetic modifications that reduce a byproduct of the biosynthetic pathway. Compositions of target products from such cells and methods of using such cells are provided.

公开(公告)号：US20240060103A1

公开(公告)日：2024-02-22

申请号：US18269689

申请日：2021-04-26

Applicant: DAESANG CORPORATION

Inventor： Jong Yun HAN ,  Chel Min YANG ,  Yong Soo KIM ,  Young Il JO

IPC: C12P17/10 ,  C12N9/10

CPC classification number: C12P17/10 ,  C12N9/1077 ,  C12Y204/02017 ,  C12R2001/19

Abstract: The present invention relates to an E. coli hisG-derived ATP-phosphoribosyltransferase variant having a reduced feedback inhibition by histidine and a strain expressing the same. The variant may maintain its activity even at a high histidine concentration, thus increasing histidine production.

公开(公告)号：US20240043380A1

公开(公告)日：2024-02-08

申请号：US18261395

申请日：2022-01-13

Applicant: CAAMTECH, INC.

Inventor： Andrew R. CHADEAYNE

IPC: C07D209/14 ,  A61K45/06 ,  C12P17/10

CPC classification number: C07D209/14 ,  A61K45/06 ,  C12P17/10

Abstract: The disclosure relates to crystalline form 1 of 5-hydroxy-N,N,N-trimethyl-tryptammonium (5-HTQ) iodide, and to pharmaceutical compositions containing the compound and to methods of treatment using it.

公开(公告)号：US11674163B2

公开(公告)日：2023-06-13

申请号：US17474777

申请日：2021-09-14

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Antonio Garrido Montalban ,  Daniel J. Buzard ,  John A. DeMattei ,  Tawfik Gharbaoui ,  Stephen R. Johannsen ,  Ashwin M. Krishnan ,  Young Mi Kuhlman ,  You-An Ma ,  Michael John Martinelli ,  Suzanne Michiko Sato ,  Dipanjan Sengupta

IPC: C12P17/10 ,  C07D209/80 ,  C07D209/94 ,  C07C17/278 ,  C07D209/88 ,  C07D295/155

CPC classification number: C12P17/10 ,  C07C17/278 ,  C07D209/80 ,  C07D209/88 ,  C07D209/94 ,  C07D295/155 ,  C07B2200/13

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

公开(公告)号：US11661617B2

公开(公告)日：2023-05-30

申请号：US17012737

申请日：2020-09-04

Applicant: COMPASS Pathfinder Limited

Inventor： Ryan Protzko

IPC: C12P17/10 ,  A61K31/4045 ,  C07D209/16 ,  C12N9/02 ,  C12N9/12 ,  C12N9/88 ,  C12N9/10

CPC classification number: C12P17/10 ,  A61K31/4045 ,  C07D209/16 ,  C12N9/0042 ,  C12N9/0071 ,  C12N9/0083 ,  C12N9/1205 ,  C12N9/88 ,  C12Y106/02004 ,  C12Y114/16004 ,  C12Y114/99 ,  C12Y207/01 ,  C12Y401/01

Abstract: Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.

公开(公告)号：US11618911B2

公开(公告)日：2023-04-04

申请号：US17830650

申请日：2022-06-02

Applicant: CODEXIS, INC.

Inventor： Haibin Chen ,  Steven J. Collier ,  Jovana Nazor ,  Joly Sukumaran ,  Derek Smith ,  Jeffrey C. Moore ,  Gregory Hughes ,  Jacob Janey ,  Gjalt W. Huisman ,  Scott J. Novick ,  Nicholas J. Agard ,  Oscar Alvizo ,  Gregory A. Cope ,  Wan Lin Yeo ,  Stefanie Ng Minor

IPC: C12N9/06 ,  C12P13/02 ,  C12P13/00 ,  C12P17/18 ,  C12P13/04 ,  C12P13/06 ,  C12P17/10 ,  C12P17/12 ,  C12P17/16

Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

公开(公告)号：US20230062510A1

公开(公告)日：2023-03-02

申请号：US17411056

申请日：2021-08-25

Applicant: Gary Zhan

Inventor： Gary Zhan

IPC: C12N15/78 ,  C12P17/10

Abstract: The present invention comprises a novel method to engineer microbes to efficiently produce the plant auxin indole-3-acetic acid. While some microorganisms including soil bacteria are known to produce indole-3-acetic acid, the yields are often very low. This technology allows the engineering of selected microbes for a strong ability to produce indole-3-acetic acid. Specifically, indole-3-acetic acid biosynthetic genes and a tryptophan transporter are expressed in a microbial host to efficiently convert tryptophan into indole-3-acetic acid. The engineered strains can be used in industry to produce this plant auxin or directly applied in agriculture to promote plant growth.

公开(公告)号：US20230022727A1

公开(公告)日：2023-01-26

申请号：US17527902

申请日：2021-11-16

Applicant: Genomatica, Inc.

Inventor： Mark J. Burk ,  Anthony P. Burgard ,  Robin E. Osterhout ,  Priti Pharkya

IPC: C12P17/10 ,  C12N1/38 ,  C12N15/52 ,  C12P7/40 ,  C12P7/44 ,  C12P13/00 ,  C12P13/02 ,  C12P17/12

Abstract: The invention provides a non-naturally occurring microbial organism having a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The invention additionally provides a method for producing 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid. The method can include culturing a 6-aminocaproic acid, caprolactam or hexametheylenediamine producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid.